Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.76 |
| ▸ | HTR2C | P28335 | 11/20 | 0.76 |
| ▸ | HTR2B | P41595 | 8/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.76 |
| ▸ | HTR1D | P28221 | 1/20 | 0.76 |
| ▸ | HTR7 | P34969 | 1/20 | 0.76 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.76 |
| ▸ | KMO | O15229 | 7/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5843607 | 1.00 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL27645810 | 0.89 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL4779282 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL31079586 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL475894 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL6088764 | 0.86 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL31079457 | 0.84 | HTR2A (0.70) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL8007696 | 0.83 | HTR2A (0.54) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069278 | 0.81 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL28069280 | 0.81 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425572-B2 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. (CH) | 2008-09-16 | — | — | US | disclosed |
| US-7129257-B1 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-10-31 | — | — | US | disclosed |
| WO-2006062839-A1 | USE OF DIOXINDOINDAZOLES AND DIOXOLOINDAZOLES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2006-03-30 | — | — | US | disclosed |
| EP-1392292-B1 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | disclosed |
| EP-1513521-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2005-03-16 | — | — | EP | disclosed |
| EP-1392292-A4 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| EP-1392292-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | disclosed |
| WO-2003101379-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2003-12-11 | — | — | WO | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| WO-2002098350-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | PTGIR, PDE3A, TBXA2R | HTR2A 3491/4885HTR2C 2389/4885HTR2B 2273/4885 |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | HTR2A 2774/4885HTR2C 2288/4885HTR2B 2644/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | HTR2A 1849/4885HTR2C 1978/4885HTR2B 1919/4885 |
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | CYP11B2, CYP11B1, PDE3A | HTR2A 3209/4885HTR2C 2047/4885HTR2B 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.